April 10, 2025

OncoBone Ltd receives significant grant funding from Business Finland

 OncoBone has received a significant R&D grant from Business Finland for further developing its Bone Metastasis Technology Platform (BMTP), a novel platform for evaluating preclinical efficacy of experimental therapies on bone metastasizing cancers. Bone metastases are life-threatening and a high unmet medical need with no curative treatments available.

Jussi Halleen, CEO of OncoBone says: “This grant funding from Business Finland came after our successful completion of a Tempo project, for which we received a grant from Business Finland last year. The continuing support of Business Finland is very important for helping OncoBone to achieve our goals for future company growth and increasing international sales. We are thankful for Business Finland for the continuing support and trust in OncoBone.”